Cargando…

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia

Children with acute myeloid leukemia (AML) have a poor prognosis despite the intensification of chemotherapy. Future efforts to improve outcomes should focus on more precise targeting of leukemia cells. CD123, or IL3RA, is expressed on the surface of nearly all pediatric AML samples and is a high-pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barwe, Sonali P., Kisielewski, Anne, Bonvini, Ezio, Muth, John, Davidson-Moncada, Jan, Kolb, Edward Anders, Gopalakrishnapillai, Anilkumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911345/ https://www.ncbi.nlm.nih.gov/pubmed/35268423 http://dx.doi.org/10.3390/jcm11051333

Ejemplares similares

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
por: Barwe, Sonali P., et al.
Publicado: (2022)

Metformin suppresses pediatric acute myeloid leukemia cell viability and clonogenicity
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2014)

Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21
por: Barwe, Sonali P., et al.
Publicado: (2022)

Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2016)

Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination
por: Lehner, Kara M., et al.
Publicado: (2023)

Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2015)

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology
por: Barwe, Sonali P., et al.
Publicado: (2020)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples
por: Barwe, Sonali P., et al.
Publicado: (2020)

Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer
por: Quagliano, Anthony, et al.
Publicado: (2020)

Tetraspanins set the stage for bone marrow microenvironment–induced chemoprotection in hematologic malignancies
por: Quagliano, Anthony, et al.
Publicado: (2023)

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
por: Gopalakrishnapillai, Anilkumar, et al.
Publicado: (2021)

Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies
por: Sidhu, Ishnoor, et al.
Publicado: (2021)

Error-corrected sequencing strategies enable comprehensive detection of leukemic mutations relevant for diagnosis and minimal residual disease monitoring
por: Crowgey, Erin L., et al.
Publicado: (2020)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
por: Xu, Xuelian, et al.
Publicado: (2011)

Corneal Epithelial Microcysts due to High-Dose Cytarabine Administration in a Pediatric Acute Myeloid Leukemia Patient
por: Karapınar, Tuba Hilkay, et al.
Publicado: (2012)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
por: Liu, Junmin, et al.
Publicado: (2022)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
por: Sun, Huali, et al.
Publicado: (2023)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
por: Rodrigues, Amanda Lopes Maia, et al.
Publicado: (2020)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
por: Serhan, Nizar, et al.
Publicado: (2020)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
por: Visser, Nienke, et al.
Publicado: (2021)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia
por: Wu, Ziliang, et al.
Publicado: (2022)

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rnsdp6cdtsckv5gnfvk1266lff